Alnylam Pharmaceuticals racked up another partnership this week, announcing that it has inked a global development and commercialization deal for its hypercholesterolemia program with The Medicines Company.

For Alnylam, the arrangement represents an important milestone in moving ahead with the program, which includes the phase I intravenous drug ALN-PCS02 and the preclinical subcutaneous agent ALN-PCSsc, as the company had previously disclosed that it would only advance the drug candidates in collaboration with a partner.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.